LISTING OF CLAIMS

Claims 1-16 (CANCELED)

17- (NEW) A "Reservoir" microcapsule composition for the delayed and controlled release of perindopril or a pharmaceutically acceptable salt thereof for oral administration, comprising:

- microparticles of perindopril or a pharmaceutically acceptable salt thereof, wherein the microparticles are each covered by at least one coating film, the coating film being formed from a composite material comprising :
  - at least one hydrophilic polymer A carrying groups ionised at neutral pH,
  - at least one hydrophobic compound B, representing a mass fraction (% by weight in relation to the total mass of the microcapsule) less than or equal to 40,
- wherein the microparticles have a diameter of less than 1200 microns.

18- (NEW) A microcapsule composition according to Claim 17, wherein the hydrophilic polymer A is selected from cellulose compounds, copolymers of methacrylic acid and a methacrylic acid ester, copolymers of methacrylic acid and an acrylic acid ester and mixtures thereof.

19- (NEW) A microcapsule compostion according to Claim 18, wherein the hydrophilic polymer A is a copolymer of methacrylic acid and methyl methacrylate or a copolymer of methacrylic acid and ethyl acrylate.

20- (NEW) A microcapsule composition according to Claim 17, wherein the hydrophobic compound B is selected from vegetable waxes, hydrogenated vegetable oils, hydrogenated triglycerides and mixtures thereof.

21- (NEW) A microcapsule composition according to Claim 17, wherein the hydrophobic compound B is a hydrogenated vegetable oil.

22- (NEW) A microcapsule composition according to Claim 17, wherein the coating film is composed of a mixture of hydrophilic polymer A and hydrophobic compound B in which the weight ratio B/A is between 0.2 and 4.

23- (NEW) A microcapsule composition according to Claim 17, wherein the coating film enables :

- at a pH of 1.4, a dissolution profile comprising a latent phase of a duration greater than or equal to half an hour, to be obtained,
- a release phase of perindopril to be obtained at any instant during the latent phase after transition from pH 1.4 to pH 6.8.

24- (NEW) A microcapsule composition according to Claim 23, wherein the latent phase is from 1 to 8 hours.

25- (NEW) A microcapsule composition according to Claim 23, wherein the latent phase is from 1 to 5 hours.

26- (NEW) A microcapsule composition according to Claim 17, wherein perindopril is in the form of a tert-butylamine salt.

27- (NEW) A microcapsule composition according to Claim 17, wherein perindopril is in the form of a arginine salt.

28- (NEW) A microcapsule composition according to Claim 26, wherein perindopril or a pharmaceutically acceptable salt thereof is deposited onto a neutral core having a diameter of from 50 to 600 microns.

29- (NEW) A microcapsule composition according to Claim 27, wherein perindopril or a pharmaceutically acceptable salt thereof is deposited onto a neutral core having a diameter of from 50 to 600 microns.

30- (NEW) A microcapsule composition according to Claim 28, wherein the neutral hydrophilic core is made of sucrose, dextrose, lactose or cellulose.

31- (NEW) A microcapsule composition according to Claim 29, wherein the neutral hydrophilic core is made of sucrose, dextrose, lactose or cellulose.

32- (NEW) A microcapsule composition according to Claim 17, wherein the perindopril microcapsules are combined with indapamide microcapsules.

33- (NEW) A method of administration of an active principle to a patient in need thereof, comprising administration of the active principle in a microencapsulated form as a component of a tablet, powder, or gelatine capsule.

34- (NEW) A pharmaceutical composition comprising as active principle an effective amount of a microcapsule composition according to claim 17 together with one or more pharmaceutically-acceptable excipients or vehicles.

35- (NEW) A pharmaceutical composition according to Claim 33 wherein the pharmaceutical composition is in the form of a tablet, powder, or gelatine capsule.

36- (NEW) A pharmaceutical composition according to Claim 34 wherein the pharmaceutical composition is in the form of a gelatin capsule.

37- (NEW) A method for treating a living animal body, including a human, afflicted with a condition selected from arterial hypertension and heart failure, comprising the step of administering to the living animal body, including a human, an amount of a pharmaceutical composition according to Claim 33 which is effective for alleviation of the condition.